Hyundai Bioscience Co., Ltd. Stock: price and insider trades · South Korea

Hyundai Bioscience Co., Ltd., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). 4 insiders have disclosed 13 filings since 31 October 2025.

Both sides are active: 2 purchases and 3 sales, from 2 insiders and 2 insiders respectively. No amount is published for 5 filings, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Those buying include 1 major shareholder.

With 13 filings in twelve months, the company is more active than the median of 7 filings across the 2,655 companies we follow on the same exchange. The full history, which starts in 2021, counts 6 purchases against 10 sales.

The most recent open-market purchase was published on 30 June 2026, 131 days ago. Filings reach the DART (FSS) feed a median of 6 days after the trade. That lag is the time during which only the insider knows about the trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.